Post: Beit Jala Pharmaceutical Reports Third Quarter Financial Results Reflecting Moderate Challenges

Beit Jala Pharmaceutical (BJP) has disclosed its financial statements for the third quarter of the year 2026, revealing a period marked by moderate financial challenges. The company, operating within the designated market category of the pharmaceutical sector, reported its data on November 12, 2026.

Beit Jala Pharmaceutical's sales for the quarter ending September 30, 2026, reached JD 9,596,898, representing an increase from JD 9,079,486 in the same period of 2025. Despite this increase in sales, the cost of sales also rose to JD 6,122,234 from the previous JD 5,486,383. Selling and distribution expenses were recorded at JD 664,592, while general and administrative expenses stood at JD 612,170, both showing an upward trend from the prior year.

According to information available from the Palestine Exchange (PEX), the company encountered a net income before tax of JD 2,038,556, a decrease from JD 2,227,725 reported in 2025. This corresponds with a net income after tax of JD 1,893,276, down from JD 2,010,072, indicating a moderate move in performance.

Additional financial details include an investment loss of JD 21,877 and a provision for anticipated credit losses amounting to JD 11,682. Financing losses were recorded at JD 33,757, coupled with foreign currency exchange losses of JD 92,030.

The company's comprehensive income was notably affected by foreign currency translation differences, which dropped to JD 673,963 from JD 1,580,990 in the previous year. The net comprehensive income reached JD 2,562,104, a significant move down from JD 3,591,062 in 2025. Overall, the results reflect the financial challenges faced by Beit Jala Pharmaceutical in the third quarter of 2026.